Maria Martínez‐Rebollar

Author

Also Known As

Berta Torres, E Martinez, E. Vdoushkina, J L Blanco, J. L. Blanco, Josep M Miró, Juan Ambrosioni, M Martínez‐Rebollar, M. Martinez-Rebollar, M. Martínez-Rebollar

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Universitat de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer Hospital Clínic de Barcelona Hospital de Sant Pau Vall d'Hebron Institut de Recerca

About

Maria Martínez‐Rebollar is an author at Universitat de Barcelona specializing in medicine, hiv, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	236
2	Epidemiology	3	3	46
3	Public Health	1	1	10
4	Social Sciences	1	1	10
5	Community Health Sciences	1	1	10

Maria Martínez‐Rebollar

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial José Ramón Arribas, Pierre‐Marie Girard, Roland Landman, The Lancet Infectious Diseases Hiv/aids CounsellingHuman RetrovirusAntiviral Drug DevelopmentAntiviral TherapyVirology	2015	142
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study Alexy Inciarte, Ana González-Cordón, Jhon Rojas, AIDS	2020	132
Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients† Montserrat Laguno, Javier Murillas, Sergio Veloso, Hepatology	2008	111
Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz, The Lancet HIV	2021	106
Tolerability of integrase inhibitors in a real-life setting Judit Peñafiel, Elisa de Lazzari, Mireia Padilla, Journal of Antimicrobial Chemotherapy	2017	103
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre Juan Ambrosioni, Jhon Rojas Liévano, Leire Berrocal, Journal of Antimicrobial Chemotherapy	2021	66
Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome Berta Torres, Pau Alcubilla, Ana González-Cordón, International Journal of Infectious Diseases	2020	55
Differences between <scp>HIV</scp>‐infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case–control studies María Dolores Calvo Sánchez, Rafel Perelló, Ignacio Pérez, HIV Medicine	2012	54
Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study Polyana Monteiro, Isidro Sanz Pérez, Montserrat Laguno, Journal of Antimicrobial Chemotherapy	2013	37
Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation Berta Torres, Alberto C. Guardo, Lorna Leal, Journal of the International AIDS Society	2014	21

Page 1